Last $67.17 USD
Change Today -0.06 / -0.09%
Volume 2.4M
STJ On Other Exchanges
New York
As of 8:04 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (STJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/7/14 - $71.90
52 Week Low
10/16/14 - $54.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ST JUDE MEDICAL INC (STJ)

st jude medical inc (STJ) Related Businessweek News

View More BusinessWeek News

st jude medical inc (STJ) Details

St. Jude Medical, Inc. develops, manufactures and distributes medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems that provide therapy to patients suffering from heart conditions, such as sudden cardiac arrest; and cardiac resynchronization therapy devices to treat patients suffering from heart failure. It also provides pacemakers for patients whose hearts beat too slowly or who suffer from other cardiac arrhythmias; leads to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment, which are used by physicians and healthcare professionals to program cardiac rhythm management devices and analyze device data to enhance patient management. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, vascular plugs, percutaneous catheter introducers, and diagnostic guidewires; and transcatheter aortic heart valves, heart valve repair and replacement products, and transcatheter structural heart defect devices. Further, it provides electrophysiology introducers and catheters, and ablation systems, as well as cardiac mapping, navigation, and recording systems for diagnosing and treating various irregular heart rhythms. Additionally, the company offers neurostimulation systems for chronic pain, such as rechargeable and primary cell implantable pulse generators. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in Saint Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/14
Founded in 1976

st jude medical inc (STJ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $430.0K
Chief Operating Officer
Total Annual Compensation: $730.0K
President of International Division
Total Annual Compensation: $752.4K
Executive Vice President
Total Annual Compensation: $730.0K
Compensation as of Fiscal Year 2013.

st jude medical inc (STJ) Key Developments

St. Jude Medical Announces CE Mark Approval of the MultiPoint Pacing Pacemaker

St. Jude Medical Inc. announced CE Mark approval of the Quadra Allure MP cardiac resynchronization therapy pacemaker (CRT-P). The Quadra Allure MP is quadripolar CRT-P with the MultiPoint Pacing option, a technology that has been shown to enhance patients response to CRT, potentially improving quality of life for patients with heart failure. The MultiPoint Pacing technology enables physicians to pace multiple locations on the left side of the heart, giving the clinician more choices to best optimize CRT pacing based on patient need and reducing the rate of CRT non-responders, as well as the likelihood of costly and invasive lead revision through a second intervention procedure. The Quadra Allure MP CRT-P is designed to work with the quarter LV lead, which has four electrodes to offer maximum flexibility for different pacing configurations to help manage heart failure patients. The MultiPoint Pacing capability allows physicians to program simultaneous or sequential delivery of two LV pulses at two different anatomical locations per pacing cycle, rather than the standard single pacing pulse, which can result in more effective resynchronization, potentially leading to better clinical outcomes compared to single site pacing.

St. Jude Medical, Inc. Announces a Retrospective Data Analysis from the Champion Clinical Trial

St. Jude Medical Inc. announced a retrospective data analysis from the CHAMPION clinical trial showing significant a reduction in 30-day hospital readmission rates for patients age 65 and older. The CHAMPION trial looked at the safety and effectiveness of the CardioMEMS(TM) HF System for patients with New York Heart Association (NYHA) Class III heart failure (HF) who had been hospitalized for HF in the previous 12 months. The analysis -- Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalization and All-Cause 30-Day Readmissions in Medicare-Eligible patients with NYHA Class III Heart Failure -- was presented during the American Heart Association Scientific Sessions. The CardioMEMS HF System uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery. This analysis looked at patients 65 and older (Medicare-eligible) from the CHAMPION trial and found that there was a 58% reduction in all-cause hospital readmissions (hospitalization for any reason) and a 78% reduction in HF hospital readmissions when patients were managed with the CardioMEMS HF System compared to standard-of-care medical management. These findings suggest that use of the CardioMEMS HF System can significantly reduce the hospital's risk of government-imposed penalties that are designed to reduce patient readmissions within 30 days of treatment.

St. Jude Medical Inc. Receives FDA Approval of TactiCath Quartz Contact Force Ablation Catheter for Treatment of Atrial Fibrillation

St. Jude Medical Inc. announced that U.S. Food and Drug Administration (FDA) approval of its TactiCath(TM) Quartz irrigated ablation catheter, the company's newest technology that gives physicians a real-time, objective measure of the force that the catheter applies to a patient's heart wall during an ablation procedure. TactiCath Quartz contact-force technology was designed to provide physicians with more control to modify that force during ablation procedures in order to create more effective lesions for patients being treated for paroxysmal atrial fibrillation (AF). The technology is associated with a reduction in the rate of AF recurrence when optimal treatment measures are used. The TactiCath Quartz ablation catheter provides electrophysiologists the ability to monitor the amount of pressure that a catheter tip exerts on the endocardium (the layer of tissue that lines the chambers of the heart). Without contact-force sensing technology, physicians have to estimate by touch with their hands the amount of force applied to the heart wall during an ablation. If too little force is applied, effective lesions may not be created and AF may recur, potentially requiring additional treatments. When too much force is applied, there is a risk of tissue injury, which can lead to serious procedure-related complications.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $67.17 USD -0.06

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $13.15 USD -0.11
Coloplast A/S kr515.50 DKK +5.50
Smith & Nephew PLC 1,089 GBp +4.00
Terumo Corp ¥2,837 JPY +72.00
Zimmer Holdings Inc $114.91 USD -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 22.2x
Price/Sales 3.4x
Price/Book 4.7x
Price/Cash Flow 21.8x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at